Amiodarone was discovered in the Labaz Laboratories in 1961, and was marketed in 1967
as an antianginal agent [48C]. This original indication and the peculiar metabolism of this …

Objective To review the clinical pharmacology, pharmacokinetics, and clinical efficacy and
safety of intravenous amiodarone. Data Identification Articles were identified through a …

Amiodarone hydrochloride appears to be one of the most effective antiarrhythmic agents
available today. It is because of its extraordinary efficacy in treating serious, life-threatening …

Cardiac arrhythmias are a cause of significant morbidity and mortality in patients with
cardiac disease, and thus represent a major management problem. The recognition that …

Amiodarone is a new antiarrhythmic drug approved for therapy of life-threatening ventricular
tachycardia and ventricular fibrillation refractory to previous antiarrhythmic therapy. The drug …

In former days, amiodarone was mainly used as high-dose prescription for serious
ventricular arrhythmias. The indication was life-saving and a high incidence of adverse …

Long term amiodarone has a very long half life and accumulates in adipose tissue and in
highly perfused organs potentially causing serious adverse reactions in these and other …

Amiodarone is a broad-spectrum, class III antiarrhythmic drug, used in the treatment of
supraventricular and ventricular arrhythmias. It is a highly lipid-soluble compound which is …